{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'NSAIDs', '-', 'Stable doses of NSAIDs are permitted during the first 12 weeks of the OLE study if', 'the subject received these NSAIDs during the core study, with dose tapering', 'permitted according to Investigator discretion. Other dose adjustments are not', 'permitted during the first 12 weeks of the OLE study unless the Investigator changes', 'the dose for safety reasons. Switching of NSAIDs is not allowed prior to Visit 4', '(Week 36) of the OLE study. However, if the subject has an AE that requires', 'discontinuation of the NSAID, an alternative NSAID may be initiated per the local', 'label (if not contraindicated).', '- Dose modification and switching of NSAIDs are permitted after Visit 4 (Week 36)', '(see Section 6.13.3).', 'Analgesics', '- Prior to Visit 4 (Week 36), subjects may be treated with paracetamol/acetaminophen', 'up to amaximum dose of 2000 mg per day (maximum 1000 mg per dose) or up to the', 'maximum dose in the local label, whichever is lower. Paracetamol/acetaminophen', 'are not to be taken within 24 hours prior to joint assessment, including OLE Baseline', 'assessment.', '-', 'After Visit 4 (Week 36), analgesics (including opioids) are permitted.', 'Inactivated vaccines can be administered in accordance with the standard of care.', '- The effect of OKZ on vaccine response, including inactivated vaccines, is unknown.', '6.13.3', 'Modification of Background Therapy', 'During the first 12 weeks of the OLE study, background MTX (all subjects) and', 'sulfasalazine and/or hydroxychloroquine (for subjects assigned rescue medication starting at', 'Week 14 in the core studies) should remain unchanged and may be adjusted only for safety', 'reasons according to Investigator discretion (see Appendix 1 [Section 13.1] for guidelines on', 'MTX dose reduction). Subjects from CL04041025 are exempt from this restriction, and have', \"their background therapy may be adjusted at the Investigator's discretion.\", 'For subjects who receive background sulfasalazine and/or hydroxychloroquine, periodic', 'safety evaluations for toxicity resulting from sulfasalazine and/or hydroxychloroquine should', 'be undertaken as per the drug label and local guidelines. The maximum allowed doses of', 'sulfasalazine and hydroxychloroquine are:', 'Sulfasalazine: 3 g per day', 'Amendment 2: 06 March 2019', '88', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Hydroxychloroquine: 400 mg per day', 'Dose tapering of background oral corticosteroids and NSAIDs (if applicable) is permitted', 'according to Investigator discretion, but the dose should otherwise remain unchanged unless', 'the Investigator changes the dose for safety reasons.', 'After the first 12 weeks of the OLE study (i.e., after Visit 4 [Week 36]), the Investigator may', 'modify background therapy, if deemed appropriate, per local guidelines. Modifications to', 'background therapy may include:', 'Modification of MTX for all subjects', 'Modification of sulfasalazine and/or hydroxychloroquine for subjects assigned rescue', 'medication starting at Week 14 in the core studies', '-', 'Sulfasalazine and/or hydroxychloroquine may not be prescribed to subjects who did', 'not receive these rescue medications in the core studies.', 'Modification of oral corticosteroids (including initiation of doses 10 mg/day of', 'prednisone or equivalent)', 'Administration of IM or IV corticosteroids', 'Modification of NSAIDs (including switching of NSAIDs)', '6.14 Medical Treatment for Subjects after End of Treatment Period', 'After completion of the 82-week, open-label Treatment Period, or after premature', 'discontinuation of study treatment, subjects will enter the Safety Follow-Up Period. It is the', 'responsibility of the Investigator to choose adequate treatment.', 'Amendment 2: 06 March 2019', '89', 'Confidential']\n\n###\n\n", "completion": "END"}